Targeting of nanoparticles in cancer: drug delivery and diagnostics

Area of Science:

• Nanomedicine and Drug Delivery
• Oncology and Cancer Therapeutics
• Biotechnology and Molecular Imaging

Background:

• Anticancer agents are crucial but often cause adverse effects due to lack of tumor specificity.
• Current imaging agents face limitations in targeting small tumors, imaging duration, and renal toxicity.
• Nanotechnology offers a promising platform for developing targeted anticancer and imaging agents.

Purpose of the Study:

• To review nanoparticle targeting strategies for enhanced delivery of anticancer and imaging agents.
• To focus on active targeting mechanisms utilizing specific targeting ligands.
• To discuss the clinical potential of nanotechnology in improving cancer treatment and diagnosis.

Main Methods:

• Review of existing literature on nanoparticle-based drug and imaging agent delivery systems.
• Analysis of passive and active targeting mechanisms for nanoparticles in cancer tissue.
• Specific focus on active targeting ligands including albumin, folic acid, transferrin, and aptamers.

Main Results:

• Nanoparticle delivery systems have demonstrated significant clinical success in targeting cancer tissue.
• Both passive and active targeting mechanisms contribute to improved agent accumulation in tumors.
• Active targeting ligands enhance specificity and efficacy by binding to cancer cell receptors.

Conclusions:

• Nanotechnology-based delivery systems are effective for targeted delivery of anticancer and imaging agents.
• Active targeting strategies using ligands like albumin, folic acid, transferrin, and aptamers show great promise.
• These targeted approaches can improve therapeutic outcomes and diagnostic accuracy while minimizing patient side effects.